Immune Profile and Network Analysis of Malaria Infection and Vaccination
Immune Profile and Network Analysis of Malaria Infection and Vaccination
批准号:
8527698
负责人:
Margaret Juliana McElrath
金额:
$48.2万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-29 至 2017-08-31
关键词:
AdultAffectAfricanAntibody FormationAntigensAntimalarialsBiometryBreedingCharacteristicsChildClinicalClinical TrialsClinical Trials DesignCommitCommunitiesCountryDNADataDevelopmentFoundationsGenetic TranscriptionGoalsGrantImmuneImmune responseImmune systemImmunityImmunizationImmunologyInfectionInformaticsInstitutionIntegration Host FactorsLaboratoriesLeadLeukocytesLifeMalariaMalaria VaccinesMethodologyMolecular ProfilingNatural ImmunityParasitesPathway AnalysisPhasePhenotypePlasmodium falciparumPopulationPopulation StudyProcessResearchResearch DesignResearch PersonnelSamplingSpecificitySterilityStrategic PlanningSystems BiologyTechnologyTimeVaccinationVaccinescell typechemokinecytokinedesignimmune functionimprovedinsightprogramsresponsevaccine developmentvaccine efficacy
中文摘要
描述(由申请人提供):现在是研制疟疾疫苗的好时机(首次表明疫苗效力的迹象,并有望在正在进行的、计划在来年进行的、并准备在赠款期间进入第1/2a阶段临床试验的试验中提供非常有效的疫苗。一个由来自强大机构和在疟疾、免疫学、系统生物学、疫苗和生物统计学方面具有互补专业知识的坚定专家组成的财团已经聚集在一起,使用现有的试验样本,以详细描述抗疟疾免疫反应及其与免疫保护的关系。这一机会吸引了那些正在进行疫苗试验并将提供临床样本的人的热情参与。这些试验的设计支持全面的免疫图谱和网络分析评估。样本将在接种疫苗和挑战或自然感染之前和之后从研究人群中获得,这些研究人群涵盖了未患疟疾的成年人、儿童和生活在流行地区的成年人。恶性疟原虫的寄生虫范围从特征良好的临床分离株(如NF54)到几个非洲国家生物多样性的自然种群。该项目将使用广泛的最佳方法来表征广泛的免疫反应和免疫细胞类型。这包括对疟疾特异性白细胞表型、细胞因子和趋化因子图谱、抗体反应以及转录和宿主DNA分析的多参数评估。这是为了生成免疫反应的概况,可以用系统生物学的方法与免疫状态和机制相关联,并确定与免疫保护相关的功能网络。这项研究旨在深入了解疟疾的保护性免疫机制,以便改进抗疟疾疫苗,并为改进疫苗的总体开发奠定基础,以便与社区共享。
相关性:一个具有互补专业知识、跨越各种高端实验室和信息学技术的研究人员联盟已经联合起来,全面描述对疟疾感染的免疫反应和免疫发展。该项目的总体目标是阐明疟疾的免疫保护机制,以加速开发广泛有效的疟疾疫苗,并从总体上推进疫苗的开发进程。
英文摘要
DESCRIPTION (provided by applicant): It Is an opportune time for malaria vaccine (development with the first indication of vaccine efficacy and the promise of very effective vaccines in trials that are underway, planned for the coming year, and poised to enter phase 1/2a clinical trials during the grant period. A consortium of committed experts from strong institutions and with complementary expertise in malaria, immunology, systems biology, vaccines, and biostatistics has assembled to use the available trial samples in order to characterize in detail antimalarial immune responses and their relationship to immune protection. This opportunity attracted the enthusiastic participation of those who are conducting vaccine trials and who will provide the clinical samples. The design of these trials supports comprehensive immune profiling and network analysis assessment. Samples will be obtained prior to and following vaccination and challenge or natural infection from study populations that span malaria-naive adults to children and adults living in endemic regions. The P. falciparum parasites range from well characterized clinical isolates (e.g. NF54) to biodiverse natural populations in several African countries. The project will use a wide range of best-of-breed methodologies to characterize a wide range of immune responses and immune cell types. This includes multi-parametric assessments of malaria specific leukocyte phenotypes, cytokine and chemokine profiles, antibody responses, and transcriptional and host DNA analyses. This is designed to generate a profiles of immune responses that can in a systems biology approach be correlated with immune status and mechanisms and identify functional networks associated with immune protection. The study is designed to provide insight into protective immune mechanisms to malaria in order to improve anti-malarial vaccines and also to lay a foundation for improved vaccine development in general that can be shared with the community.
RELEVANCE: A consortium of investigators with complementary expertise that span a wide range of high-end laboratory and informatic technologies have joined forces to comprehensively profile immune responses to malaria infection and the development of immunity. The overall goal of this project is to elucidate the mechanisms of immune protection to malaria in order to accelerate development of a broadly effective malaria vaccine and to advance the process of vaccine development in general.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3
-
批准号:10570748
-
项目类别:
-
资助金额:$58.69万
-
财政年份:2022
-
负责人:Margaret Juliana McElrath
-
依托单位:
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
-
批准号:10570806
-
项目类别:
-
资助金额:$132.48万
-
财政年份:2022
-
负责人:Margaret Juliana McElrath
-
依托单位:
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Lab
-
批准号:10322580
-
项目类别:
-
资助金额:$1498.01万
-
财政年份:2021
-
负责人:Margaret Juliana McElrath
-
依托单位:
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC
-
批准号:10165321
-
项目类别:
-
资助金额:$2995.23万
-
财政年份:2020
-
负责人:Margaret Juliana McElrath
-
依托单位:
SARS-CoV-2 testing at the Seattle Vaccine and Prevention CRS (30331)
-
批准号:10166485
-
项目类别:
-
资助金额:$29.94万
-
财政年份:2020
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core
-
批准号:10419582
-
项目类别:
-
资助金额:$17.68万
-
财政年份:2017
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization
-
批准号:10419580
-
项目类别:
-
资助金额:$207.15万
-
财政年份:2017
-
负责人:Margaret Juliana McElrath
-
依托单位:
Scientific Project 2: HIV AIDS Defining molecular signatures in humans following vaccination that can inform pathways to protective immunity against HIV-1 infection
-
批准号:10419585
-
项目类别:
-
资助金额:$20.45万
-
财政年份:2017
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core
-
批准号:10198679
-
项目类别:
-
资助金额:$16.28万
-
财政年份:2017
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core
-
批准号:10631089
-
项目类别:
-
资助金额:$18.52万
-
财政年份:2017
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune responses to HIV virus immunization - Project 2
-
批准号:10198682
-
项目类别:
-
资助金额:$59.64万
-
财政年份:2017
-
负责人:Margaret Juliana McElrath
-
依托单位:
Scientific Project 2: HIV AIDS Defining molecular signatures in humans following vaccination that can inform pathways to protective immunity against HIV-1 infection
-
批准号:10631105
-
项目类别:
-
资助金额:$13.48万
-
财政年份:2017
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization
-
批准号:10631086
-
项目类别:
-
资助金额:$210.0万
-
财政年份:2017
-
负责人:Margaret Juliana McElrath
-
依托单位:
HIV-1 Cellular Immunity in Exposed Seronegatives
-
批准号:8086448
-
项目类别:
-
资助金额:$18.49万
-
财政年份:2010
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Profile and Network Analysis of Malaria Infection and Vaccination
-
批准号:9129262
-
项目类别:
-
资助金额:$24.63万
-
财政年份:2010
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Profile and Network Analysis of Malaria Infection and Vaccination
-
批准号:8150942
-
项目类别:
-
资助金额:$51.81万
-
财政年份:2010
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Signatures Associated with Plasmodium falciparum Control Following Natural
-
批准号:7994286
-
项目类别:
-
资助金额:$28.66万
-
财政年份:2010
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Profile and Network Analysis of Malaria Infection and Vaccination
-
批准号:7977154
-
项目类别:
-
资助金额:$52.3万
-
财政年份:2010
-
负责人:Margaret Juliana McElrath
-
依托单位:
Immune Profile and Network Analysis of Malaria Infection and Vaccination
-
批准号:8316314
-
项目类别:
-
资助金额:$51.28万
-
财政年份:2010
-
负责人:Margaret Juliana McElrath
-
依托单位:
Seattle-Lausanne Clinical Trials Unit
-
批准号:10531278
-
项目类别:
-
资助金额:$185.72万
-
财政年份:2007
-
负责人:Margaret Juliana McElrath
-
依托单位:
海外基金